The Emergency Department, Qingdao Chengyang District People's Hospital, Qingdao, China.
PeerJ. 2023 Aug 25;11:e15933. doi: 10.7717/peerj.15933. eCollection 2023.
This study aimed to investigate the correlation between serum levels of macrophage migration inhibitory factor (MIF) and the condition and prognosis of patients with traumatic brain injury (TBI).
A retrospective study design was used, and the clinical data of 131 TBI patients from February 2019 to January 2022 were analyzed. Patients were divided into mild (13-15 points), moderate (9-12 points), or severe (3-8 points) groups according to their Glasgow Coma Scale (GCS) score after admission. The serum levels of BDNF, MIF, and MBP in the three groups were compared, and their correlation with the severity of TBI was analyzed. Patients were then separated into a good prognosis group (4-5 points) and a poor prognosis group (≤3 points) based on their Glasgow Prognostic Score (GOS) after 6 months of follow-up. The predictive power of serum indexes and combined detection on prognosis was analyzed.
Patients were classified into a mild group ( = 63), moderate group ( = 47), and severe group ( = 21) based on their GCS, with a significant difference noted in serum levels of MIF, MBP, and BDNF among patients with different degrees of severity (all < 0.001). The MIF, MBP, and BDNF levels were lower in the mild group compared to the moderate (all < 0.001) and severe group (all < 0.001). Additionally, the MIF and BDNF levels in the moderate group were lower compared to the severe group ( = 0.011, = 0.002). Patients with mild severity had lower serum MIF, MBP, and BDNF levels than those with other degrees, and these indexes were positively correlated with the severity of TBI (all < 0.001, r = 0.62, r = 0.48, r = 0.58). Based on the GOS, patients were divided into a good prognosis group ( = 107) and a poor prognosis group ( = 24), with the levels of MIF, MBP, and BDNF in the good prognosis group being significantly lower than those in the poor prognosis group ( < 0.001, = 0.007, = 0.003). The area under the curve (AUC) of MIF was higher than that of MBP and BDNF in predicting the prognosis of TBI patients; however, the statistical differences were not significant (MIF . MBP, = 0.239; MIF . BDNF, = 0.211; BDNF . MBP, = 0.899). The center line has a large displacement, CT annular cisterna compression, increased white blood cell count, MBP and BDNF were risk factors for prognosis in TBI patients ( = 0.005, = 0.001, = 0.005, = 0.033, = 0.044).
The serum levels of MIF, MBP, and BDNF in TBI patients were positively correlated with the severity of the disease, and MBP, BDNF levels had predictive value in determining patient prognosis.
本研究旨在探讨血清巨噬细胞移动抑制因子（MIF）水平与创伤性脑损伤（TBI）患者病情和预后的关系。
采用回顾性研究设计，分析了 2019 年 2 月至 2022 年 1 月期间 131 例 TBI 患者的临床资料。根据入院后格拉斯哥昏迷量表（GCS）评分，患者分为轻度（13-15 分）、中度（9-12 分）或重度（3-8 分）组。比较三组患者血清 BDNF、MIF 和 MBP 水平，并分析其与 TBI 严重程度的相关性。然后，根据患者在 6 个月随访后的格拉斯哥预后评分（GOS），将其分为预后良好组（4-5 分）和预后不良组（≤3 分）。分析血清指标及其联合检测对预后的预测能力。
根据 GCS 将患者分为轻度组（n=63）、中度组（n=47）和重度组（n=21），不同严重程度患者血清 MIF、MBP 和 BDNF 水平差异有统计学意义（均 <0.001）。与中度组和重度组相比，轻度组 MIF、MBP 和 BDNF 水平均较低（均 <0.001）。此外，中度组 MIF 和 BDNF 水平低于重度组（=0.011，=0.002）。轻度组患者血清 MIF、MBP 和 BDNF 水平低于其他严重程度组，且与 TBI 严重程度呈正相关（均 <0.001，r=0.62，r=0.48，r=0.58）。根据 GOS，患者分为预后良好组（n=107）和预后不良组（n=24），预后良好组 MIF、MBP 和 BDNF 水平明显低于预后不良组（均 <0.001，=0.007，=0.003）。MIF 的曲线下面积（AUC）预测 TBI 患者预后的效能高于 MBP 和 BDNF，但差异无统计学意义（MIF. MBP，=0.239；MIF. BDNF，=0.211；BDNF. MBP，=0.899）。中线有较大位移、CT 环池受压、白细胞计数升高、MBP 和 BDNF 是 TBI 患者预后的危险因素（均 <0.005，=0.001，=0.005，=0.033，=0.044）。
TBI 患者血清 MIF、MBP 和 BDNF 水平与疾病严重程度呈正相关，MBP、BDNF 水平对判断患者预后具有预测价值。
